Navigation Links
NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
Date:10/15/2008

oscience, chairman of the department of neuroscience and director of the Brain Institute at the Mount Sinai School of Medicine, in New York. The goal of Dr. Nestler's research is to better understand the molecular mechanisms of addiction and depression. He uses animal models to identify the ways in which drugs of abuse or stress change the brain to lead to addiction- or depression-like syndromes, information that helps him to develop improved treatments. From 2000 to 2008, he was Distinguished Professor and chair of the department of psychiatry at the University of Texas Southwestern Medical Center at Dallas and before that, for 18 years, professor of psychiatry, pharmacology and neurobiology at Yale University, where he also directed the Abraham Ribicoff Research Facilities and the Division of Molecular Psychiatry.

"Dr. Nestler has demonstrated a remarkable ability to focus on basic science that is directly relevant to severe forms of mental illness," commented Jack D. Barchas, M.D., Barklie McKee Henry Professor and Chair of Psychiatry, Weill-Cornell Medical College, who heads NARSAD's Goldman-Rakic Prize Selection Committee. "He has led research with direct relevance to fundamental processes in brain development, as well as our understanding of disorders such as depression and drug abuse."

NARSAD's 2008 Sidney R. Baer, Jr. Prize for Schizophrenia Research will be presented to Angus W. MacDonald, III, Ph.D., associate professor of psychology and director of the Translational Research in Cognitive and Affective Mechanisms Laboratory at the University of Minnesota. Dr. MacDonald's research focuses on understanding the genetic and neural causes of schizophrenia, and also encompasses ways in which patients can improve their brain and real-world functioning. In earlier research, he used functional neuroimaging to identify brain regions different in patients with schizophrenia and examined whether these same regions were affected in healthy people wit
'/>"/>

Contact: Kristen Simone
ksimone@narsad.org
516-829-0091
NARSAD, The Mental Health Research Association
Source:Eurekalert

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
2. At Boston symposium, NARSAD researchers report on genes and family traits
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. LaserCard Corporation Announces Expansion of Middle East Project
5. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
6. Balzan Foundation announces 2007 winners
7. The American Society of Plant Biologists announces 2007 awards
8. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
9. NIST announces 56 new awards for innovative technology research and development
10. Titanium Group Announces Contract With Haitong Securities
11. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3